drugset / Trial / NCT01085344
Canadian Hemophilia Prophylaxis Study
NaSingle-groupOpen-labelTreatment
Summary
Primary prophylaxis given less frequently initially, with the infusion frequency increased if needed (Escalating Dose Prophylaxis), is likely to be less expensive and associated with fewer complications than standard prophylaxis while reducing disability to a greater degree than intermittent therapy.
Timeline
- Start
- 1997-06-26
- Primary completion
- 2012-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADVATE | Protein / enzyme biologic | — | — |